PTC Therapeutics
PTC faces FDA hurdles for two drug candidates, delays filing
Anika Sharma
PTC Therapeutics finds itself in a regulatory whirlwind, as the latest third-quarter results reveal hurdles and setbacks impacting the biotech’s ...
PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B
Anika Sharma
As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...
PTC cuts jobs as Europe withdraws approval for its DMD drug
Anika Sharma
PTC Therapeutics has announced an expansion of its previously planned workforce reductions as European regulatory concerns cast a shadow over ...
PTC Therapeuticsâ Translarna at risk of losing EU approval after failing to impress FDA for DMD
Anika Sharma
PTC Therapeutics is facing a significant setback as it seeks to maintain approval for its Duchenne muscular dystrophy (DMD) therapy, ...
